Aimed at individuals who are 50+, the ease and thoroughness of the test process can help detect difficult-to-diagnose cancers when they're in their early stages such as some blood cancers, ovarian, head and neck, and pancreatic cancer.

Developed by a U.S. biotech company called Grail, the trials of around 3,000 people looked for small leaks of altered DNA that seep from tumors into the bloodstream. It uses machine learning, a type of artificial intelligence, to look for changes in DNA "methylation."

DNA Methylation is a record of the changes—often through damage, which DNA experiences over its lifetime—and is being theorized as a possible detector of cancer, but also as the truest marker of biological aging.

Earlier versions of this test detected cancers in their early stages on average at 18%, but more advanced stages at 93%. Some cancers, like pancreatic, were detected with 63% accuracy even at stage 1.